Listed

Arcturus Therapeutics Holdings Inc.

ARCTNasdaqCIK 1768224HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$3.0m, Q2 FY2026
Operating income−$25.5m, Q2 FY2026
Net income−$23.8m, Q2 FY2026
Arcturus Therapeutics Holdings Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m45.1Revenue, Q3 FY2023, three months to 2023-09-30$45.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figure30.9Revenue, Q4 FY2023, three months to 2023-12-31$30.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure38.0Revenue, Q1 FY2024, three months to 2024-03-31$38.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure49.9Revenue, Q2 FY2024, three months to 2024-06-30$49.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-11, accession 0000950170-25-106560.Report this figure41.7Revenue, Q3 FY2024, three months to 2024-09-30$41.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure22.8Revenue, Q4 FY2024, three months to 2024-12-31$22.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure29.4Revenue, Q1 FY2025, three months to 2025-03-31$29.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure28.3Revenue, Q2 FY2025, three months to 2025-06-30$28.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure17.2Revenue, Q3 FY2025, three months to 2025-09-30$17.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure7.2Revenue, Q4 FY2025, three months to 2025-12-31$7.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure2.1Revenue, Q1 FY2026, three months to 2026-03-31$2.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure3.0Revenue, Q2 FY2026, three months to 2026-06-30$3.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure
Research and development$m51.1Research and development, Q3 FY2023, three months to 2023-09-30$51.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figure36.6Research and development, Q4 FY2023, three months to 2023-12-31$36.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure53.6Research and development, Q1 FY2024, three months to 2024-03-31$53.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure58.7Research and development, Q2 FY2024, three months to 2024-06-30$58.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0000950170-25-106560.Report this figure39.1Research and development, Q3 FY2024, three months to 2024-09-30$39.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure43.8Research and development, Q4 FY2024, three months to 2024-12-31$43.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure34.9Research and development, Q1 FY2025, three months to 2025-03-31$34.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure29.6Research and development, Q2 FY2025, three months to 2025-06-30$29.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure23.3Research and development, Q3 FY2025, three months to 2025-09-30$23.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure24.5Research and development, Q4 FY2025, three months to 2025-12-31$24.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure21.5Research and development, Q1 FY2026, three months to 2026-03-31$21.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure17.5Research and development, Q2 FY2026, three months to 2026-06-30$17.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure
Operating income$m(19.3)Operating income, Q3 FY2023, three months to 2023-09-30−$19.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figure(18.3)Operating income, Q4 FY2023, three months to 2023-12-31−$18.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure(30.4)Operating income, Q1 FY2024, three months to 2024-03-31−$30.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure(21.1)Operating income, Q2 FY2024, three months to 2024-06-30−$21.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0000950170-25-106560.Report this figure(10.7)Operating income, Q3 FY2024, three months to 2024-09-30−$10.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure(33.4)Operating income, Q4 FY2024, three months to 2024-12-31−$33.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure(16.8)Operating income, Q1 FY2025, three months to 2025-03-31−$16.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure(11.6)Operating income, Q2 FY2025, three months to 2025-06-30−$11.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure(16.5)Operating income, Q3 FY2025, three months to 2025-09-30−$16.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure(31.3)Operating income, Q4 FY2025, three months to 2025-12-31−$31.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure(28.9)Operating income, Q1 FY2026, three months to 2026-03-31−$28.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure(25.5)Operating income, Q2 FY2026, three months to 2026-06-30−$25.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure
Income tax$m0.9Income tax, Q3 FY2023, three months to 2023-09-30$893.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figure0.3Income tax, Q4 FY2023, three months to 2023-12-31$262.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure0.4Income tax, Q1 FY2024, three months to 2024-03-31$368.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure(0.2)Income tax, Q2 FY2024, three months to 2024-06-30−$150.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-11, accession 0000950170-25-106560.Report this figure(0.2)Income tax, Q3 FY2024, three months to 2024-09-30−$217.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure(0.0)Income tax, Q4 FY2024, three months to 2024-12-31−$4.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$4.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-12, accession 0001193125-25-275758. Derived: 9-month figure less the 6-month figure.Report this figurenot reportednot reported0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure
Net income$m(16.2)Net income, Q3 FY2023, three months to 2023-09-30−$16.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figure(11.7)Net income, Q4 FY2023, three months to 2023-12-31−$11.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure(26.8)Net income, Q1 FY2024, three months to 2024-03-31−$26.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure(17.2)Net income, Q2 FY2024, three months to 2024-06-30−$17.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure(6.9)Net income, Q3 FY2024, three months to 2024-09-30−$6.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure(30.0)Net income, Q4 FY2024, three months to 2024-12-31−$30.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure(14.1)Net income, Q1 FY2025, three months to 2025-03-31−$14.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure(9.2)Net income, Q2 FY2025, three months to 2025-06-30−$9.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure(13.4)Net income, Q3 FY2025, three months to 2025-09-30−$13.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure(29.1)Net income, Q4 FY2025, three months to 2025-12-31−$29.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure(27.0)Net income, Q1 FY2026, three months to 2026-03-31−$27.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure(23.8)Net income, Q2 FY2026, three months to 2026-06-30−$23.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure
Diluted EPS$ per share(0.61)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.61 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figurenot reported(1.00)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure(0.64)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0000950170-25-106560.Report this figure(0.26)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figurenot reported(0.52)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure(0.34)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure(0.49)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figurenot reported(0.95)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.95 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure(0.84)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure
Basic EPS$ per share(0.61)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.61 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figurenot reported(1.00)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure(0.64)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0000950170-25-106560.Report this figure(0.26)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figurenot reported(0.52)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure(0.34)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure(0.49)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.49 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figurenot reported(0.95)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.95 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure(0.84)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.84 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure

Balance sheet

Cash and equivalents$191.5m, Q2 FY2026
Long-term debt$15.0m, Q1 FY2025
Shareholders' equity$171.8m, Q2 FY2026
Arcturus Therapeutics Holdings Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m312Cash and equivalents, Q3 FY2023, at 2023-09-30$311.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figure292Cash and equivalents, FY2023, at 2023-12-31$292.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-03, accession 0001193125-26-088391.Report this figure288Cash and equivalents, Q1 FY2024, at 2024-03-31$288.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure260Cash and equivalents, Q2 FY2024, at 2024-06-30$260.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0000950170-25-106560.Report this figure237Cash and equivalents, Q3 FY2024, at 2024-09-30$237.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure237Cash and equivalents, FY2024, at 2024-12-31$237.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-03, accession 0001193125-26-088391.Report this figure217Cash and equivalents, Q1 FY2025, at 2025-03-31$216.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure196Cash and equivalents, Q2 FY2025, at 2025-06-30$196.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure180Cash and equivalents, Q3 FY2025, at 2025-09-30$180.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure231Cash and equivalents, FY2025, at 2025-12-31$230.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure211Cash and equivalents, Q1 FY2026, at 2026-03-31$211.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure191Cash and equivalents, Q2 FY2026, at 2026-06-30$191.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure
Current assets$m393Current assets, Q3 FY2023, at 2023-09-30$393.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0000950170-23-063778.Report this figure387Current assets, FY2023, at 2023-12-31$386.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-06, accession 0000950170-25-034787.Report this figure376Current assets, Q1 FY2024, at 2024-03-31$375.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-08, accession 0000950170-24-055702.Report this figure347Current assets, Q2 FY2024, at 2024-06-30$347.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-05, accession 0000950170-24-090905.Report this figure331Current assets, Q3 FY2024, at 2024-09-30$330.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figure306Current assets, FY2024, at 2024-12-31$306.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-03, accession 0001193125-26-088391.Report this figure279Current assets, Q1 FY2025, at 2025-03-31$278.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure275Current assets, Q2 FY2025, at 2025-06-30$274.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0000950170-25-106560.Report this figure249Current assets, Q3 FY2025, at 2025-09-30$249.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure241Current assets, FY2025, at 2025-12-31$241.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure217Current assets, Q1 FY2026, at 2026-03-31$216.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure197Current assets, Q2 FY2026, at 2026-06-30$197.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure
Total assets$m458Total assets, Q3 FY2023, at 2023-09-30$457.6m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0000950170-23-063778.Report this figure429Total assets, FY2023, at 2023-12-31$429.4m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-06, accession 0000950170-25-034787.Report this figure419Total assets, Q1 FY2024, at 2024-03-31$418.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-08, accession 0000950170-24-055702.Report this figure389Total assets, Q2 FY2024, at 2024-06-30$388.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-05, accession 0000950170-24-090905.Report this figure371Total assets, Q3 FY2024, at 2024-09-30$370.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figure344Total assets, FY2024, at 2024-12-31$344.1m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-03, accession 0001193125-26-088391.Report this figure332Total assets, Q1 FY2025, at 2025-03-31$331.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure309Total assets, Q2 FY2025, at 2025-06-30$309.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0000950170-25-106560.Report this figure282Total assets, Q3 FY2025, at 2025-09-30$282.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure271Total assets, FY2025, at 2025-12-31$271.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure245Total assets, Q1 FY2026, at 2026-03-31$245.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure224Total assets, Q2 FY2026, at 2026-06-30$224.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure
Current liabilities$m87.7Current liabilities, Q3 FY2023, at 2023-09-30$87.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0000950170-23-063778.Report this figure82.0Current liabilities, FY2023, at 2023-12-31$82.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-06, accession 0000950170-25-034787.Report this figure115Current liabilities, Q1 FY2024, at 2024-03-31$115.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-08, accession 0000950170-24-055702.Report this figure91.7Current liabilities, Q2 FY2024, at 2024-06-30$91.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-05, accession 0000950170-24-090905.Report this figure69.5Current liabilities, Q3 FY2024, at 2024-09-30$69.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figure65.5Current liabilities, FY2024, at 2024-12-31$65.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-03, accession 0001193125-26-088391.Report this figure49.4Current liabilities, Q1 FY2025, at 2025-03-31$49.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure46.5Current liabilities, Q2 FY2025, at 2025-06-30$46.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0000950170-25-106560.Report this figure31.7Current liabilities, Q3 FY2025, at 2025-09-30$31.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure36.4Current liabilities, FY2025, at 2025-12-31$36.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure34.4Current liabilities, Q1 FY2026, at 2026-03-31$34.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure33.5Current liabilities, Q2 FY2026, at 2026-06-30$33.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure
Total liabilities$m178Total liabilities, Q3 FY2023, at 2023-09-30$177.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0000950170-23-063778.Report this figure151Total liabilities, FY2023, at 2023-12-31$150.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-06, accession 0000950170-25-034787.Report this figure155Total liabilities, Q1 FY2024, at 2024-03-31$154.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-08, accession 0000950170-24-055702.Report this figure130Total liabilities, Q2 FY2024, at 2024-06-30$130.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-05, accession 0000950170-24-090905.Report this figure109Total liabilities, Q3 FY2024, at 2024-09-30$108.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figure103Total liabilities, FY2024, at 2024-12-31$103.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-03, accession 0001193125-26-088391.Report this figure98.0Total liabilities, Q1 FY2025, at 2025-03-31$98.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure78.2Total liabilities, Q2 FY2025, at 2025-06-30$78.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0000950170-25-106560.Report this figure57.8Total liabilities, Q3 FY2025, at 2025-09-30$57.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure57.2Total liabilities, FY2025, at 2025-12-31$57.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure54.0Total liabilities, Q1 FY2026, at 2026-03-31$54.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure52.5Total liabilities, Q2 FY2026, at 2026-06-30$52.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure
Long-term debt$m20.0Long-term debt, Q3 FY2023, at 2023-09-30$20.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2023-11-14, accession 0000950170-23-063778.Report this figurenot reportednot reportednot reportednot reportednot reported15.0Long-term debt, Q1 FY2025, at 2025-03-31$15.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figurenot reportednot reportednot reportednot reportednot reported
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m280Shareholders' equity, Q3 FY2023, at 2023-09-30$280.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figure279Shareholders' equity, FY2023, at 2023-12-31$278.5m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-03, accession 0001193125-26-088391.Report this figure264Shareholders' equity, Q1 FY2024, at 2024-03-31$264.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure259Shareholders' equity, Q2 FY2024, at 2024-06-30$258.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure262Shareholders' equity, Q3 FY2024, at 2024-09-30$261.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure241Shareholders' equity, FY2024, at 2024-12-31$241.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure234Shareholders' equity, Q1 FY2025, at 2025-03-31$233.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure231Shareholders' equity, Q2 FY2025, at 2025-06-30$231.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure225Shareholders' equity, Q3 FY2025, at 2025-09-30$224.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure214Shareholders' equity, FY2025, at 2025-12-31$214.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure191Shareholders' equity, Q1 FY2026, at 2026-03-31$191.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure172Shareholders' equity, Q2 FY2026, at 2026-06-30$171.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure

Cash flow

Operating cash flow−$19.9m, Q2 FY2026
Capital expenditure$0, Q2 FY2026
Arcturus Therapeutics Holdings Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(32.4)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$32.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0000950170-24-123469. Derived: 9-month figure less the 6-month figure.Report this figure(0.6)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$629.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure(5.6)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$5.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure(30.1)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$30.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0000950170-25-106560. Derived: 6-month figure less the 3-month figure.Report this figure(23.8)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$23.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-275758. Derived: 9-month figure less the 6-month figure.Report this figure(0.3)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$284.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure(35.1)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$35.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure(5.8)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$5.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-338090. Derived: 6-month figure less the 3-month figure.Report this figure(17.2)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$17.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-275758. Derived: 9-month figure less the 6-month figure.Report this figure(16.2)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$16.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure(19.4)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$19.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure(19.9)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$19.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-338090. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m1.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$981.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-07, accession 0000950170-24-123469. Derived: 9-month figure less the 6-month figure.Report this figure0.9Capital expenditure, Q4 FY2023, three months to 2023-12-31$875.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2024, three months to 2024-03-31$240.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure0.3Capital expenditure, Q2 FY2024, three months to 2024-06-30$328.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-11, accession 0000950170-25-106560. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2024, three months to 2024-09-30$80.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001193125-25-275758. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$137.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-338090. Derived: 6-month figure less the 3-month figure.Report this figure0.2Capital expenditure, Q3 FY2025, three months to 2025-09-30$181.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001193125-25-275758. Derived: 9-month figure less the 6-month figure.Report this figure(0.1)Capital expenditure, Q4 FY2025, three months to 2025-12-31−$88.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001193125-26-088391. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-338090. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)28.42m, Q2 FY2026
Arcturus Therapeutics Holdings Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.0Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3026,467 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0000950170-23-063778.Report this figure27.1Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3127,149,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-08, accession 0000950170-24-055702.Report this figure26.6Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3026,563,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-05, accession 0000950170-24-090905.Report this figure26.6Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3026,574,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0000950170-24-123469.Report this figure26.9Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3126,879,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0000950170-25-069210.Report this figure27.0Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3026,967,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0000950170-25-106560.Report this figure27.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3027,062,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure27.1Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3127,107,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure27.1Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3027,129,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure27.2Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3027,188,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-275758.Report this figure28.4Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3128,421,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-211943.Report this figure28.4Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3028,423,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure

Shares outstanding: 28.42mShares outstanding, period not labelled, at 2026-08-0428,423,069 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-338090.Report this figure at Aug 4, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.